Form 4: Immunovant Director Jake Bauer Reports Stock and Option Awards

Director Jake Bauer received stock options and restricted stock units from Immunovant, Inc. on May 1, 2025, according to a Form 4 filing.

Summary

• On May 1, 2025, Jake Bauer, a director of Immunovant, Inc., was granted 25,016 restricted stock units (RSUs) and options to purchase 35,234 shares of common stock.
• The RSUs and options were granted under Immunovant's 2019 Equity Incentive Plan.
• The RSUs represent a contingent right to receive one share of common stock upon vesting.
• Both the RSUs and the options vest in three equal annual installments starting on May 1, 2025, contingent upon continuous service to the Issuer.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard compensation practices. The vesting schedule suggests a long-term commitment from the director.

Positives

• The grant of RSUs and stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service to the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the granted securities.

Industry Context

The granting of stock options and RSUs to directors is a common practice in the biotechnology industry to incentivize and retain key personnel.

Stakeholder Impact

• The grant of equity to a director can align their interests with those of shareholders, potentially leading to better decision-making for the company's long-term success.

Key Dates

Keywords

Immunovant, Jake Bauer, Director, Form 4, Stock Options, Restricted Stock Units, Equity Incentive Plan, Vesting